CARdioprotection in Myocardial Infarction (NCT02967965) | Clinical Trial Compass
UnknownNot Applicable
CARdioprotection in Myocardial Infarction
France2,000 participantsStarted 2013-11-30
Plain-language summary
CARIM is a prospective cohort of 2,000 patients with a first myocardial infarction and undergoing reperfusion therapy. Therefore, male and female patients older than 18 years and younger than 90 years with onset of chest pain of less than 12 hours who need a primary percutaneous coronary intervention (PCI) for a ST elevation segment MI (STEMI) will be recruited.
Who can participate
Age range18 Years – 90 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Any patient hospitalized in the cardiology department of the participating centers
* Who have signed the Informed Consent Form.
* Patient having health insurance.
* Requiring PCI for reperfusion.
* With a diagnosis of a first MI.
* With ST segment elevation and/or Q wave at admission.
* With troponin elevation.
* Seen within the first 12 hours after symptom onset.
* Aged between 18 and 90 years.
Exclusion Criteria:
* Refusal of the patient.
* In case of poor echogenicity, the participation of the patient will be stopped.
* Patient with diagnosis of previous MI, or hypertrophic or dilated cardiomyopathy, or significant valvular heart disease, or chronic atrial fibrillation, or pace maker or any permanent implanted device susceptible to interfere with LV remodeling.
* Patient with preexisting heart failure.
* Patient with any previous cardiac surgery.
* Patient with previous chemotherapy susceptible to induce LV remodeling (anthracyclines).
* Patient with an associated short-time life-threatening disease.
* Pregnant or breast-feeding patient.
* Contra-indication to MRI (claustrophobia, pacemaker or any other metallic implants, creatinin clearance \< 30mL/min/1.73m2 MDRD).